Wide Ranks

GLMD

Galmed Pharmaceuticals Ltd.

2.86

Top Statistics
Market Cap 4 M Forward PE -2.78 Revenue Growth 0.00 %
Current Ratio 6.48 Trailing PE 0.0410 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 1.35 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 9 M Total Cash Per Share 18.54 Total Debt
Total Debt To Equity Current Ratio 6.48 Book Value Per Share 33.01
All Measures
Short Ratio 27.00 % Message Board Id finmb_114779940 Shares Short Prior Month 34164
Return On Equity -0.5267 City Ramat Gan Uuid ade4d27e-0850-308a-ae7b-98b5c772bca9
Previous Close 2.87 First Trade Date Epoch Utc 1 B Book Value 33.01
Beta 0.7980 Volume 53993 Price To Book 0.0866
Last Split Date 1 B Fifty Two Week Low 2.68 Total Cash Per Share 18.54
Shares Short Previous Month Date 1 B Max Age 86400 Sand P52 Week Change 0.3133
Net Income To Common -5883000 Short Percent Of Float 0.0308 Implied Shares Outstanding 1 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 36970
Average Volume10days 36970 Total Cash 9 M Next Fiscal Year End 1 B
Held Percent Insiders 0.0129 Trailing PE 0.0410 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 2.87 Target Low Price 0.0000
Gmt Off Set Milliseconds -18000000 Fifty Day Average 4.30 Open 2.90
Free Cashflow -4066250 Dividend Yield 0.00 % Return On Assets -0.2931
Time Zone Short Name EST Trailing Eps 69.72 Day Low 2.71
Address1 16 Abba Hillel Road Shares Outstanding 1 M Price Hint 4
Target High Price 0.0000 Website https://www.galmedpharma.com 52 Week Change -0.3286
Average Volume 2 M Forward Eps -1.03 Recommendation Key none
Compensation As Of Epoch Date 1 B Quick Ratio 640.80 % Last Split Factor 1:12
Regular Market Day High 2.91 Is_sp_500 False Profit Margins 0.00 %
Fifty Two Week High 23.80 Day High 2.91 Shares Short 45883
Regular Market Open 2.90 Industry Key biotechnology Earnings Growth 0.00 %
Revenue Growth 0.00 % Shares Percent Shares Out 0.0304 Operating Cashflow -5922000
Currency USD Time Zone Full Name America/New_York Market Cap 4 M
Is_nasdaq_100 False Zip 5250608 Quote Type EQUITY
Industry Biotechnology Long Name Galmed Pharmaceuticals Ltd. Regular Market Day Low 2.71
Held Percent Institutions 0.0049 Current Price 2.86 Enterprise To Ebitda 1.35
Financial Currency USD Current Ratio 6.48 Industry Disp Biotechnology
Country Israel Float Shares 523081 Two Hundred Day Average 4.20
Enterprise Value -8270407 Forward PE -2.78 Regular Market Volume 53993
Ebitda -6145000 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Galmed Pharmaceuticals Ltd.

, a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases.

It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus.

The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy.

In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine.

Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis.

It has a license agreement with Samil Pharma.

Co.

, Ltd.

for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform.

Galmed Pharmaceuticals Ltd.

was founded in 2000 and is headquartered in Ramat Gan, Israel.